TRIM44 activates the AKT/mTOR signal pathway to induce melanoma progression by stabilizing TLR4
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
TRIM44 activates the AKT/mTOR signal pathway to induce melanoma progression by stabilizing TLR4
Authors
Keywords
TRIM44, Melanoma, EMT, Prognosis, TLR4, AKT/mTOR pathway
Journal
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Volume 38, Issue 1, Pages -
Publisher
Springer Nature
Online
2019-03-28
DOI
10.1186/s13046-019-1138-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- TRIM44, a crucial target of miR-410, functions as a potential oncogene in osteosarcoma
- (2018) Heng Wang et al. OncoTargets and Therapy
- microRNA-501-3p suppresses metastasis and progression of hepatocellular carcinoma through targeting LIN7A
- (2018) Chubin Luo et al. Cell Death & Disease
- Elevated TRIM44 promotes intrahepatic cholangiocarcinoma progression by inducing cell EMT via MAPK signaling
- (2018) Rui Peng et al. Cancer Medicine
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- TRIM44 promotes human esophageal cancer progression via the AKT/mTOR pathway
- (2018) Dian Xiong et al. CANCER SCIENCE
- Melanoma
- (2018) Dirk Schadendorf et al. LANCET
- TRIM44 promotes quiescent multiple myeloma cell occupancy and survival in the osteoblastic niche via HIF-1α stabilization
- (2018) Zheng Chen et al. LEUKEMIA
- Bioinformatics-based analysis reveals elevated MFSD12 as a key promoter of cell proliferation and a potential therapeutic target in melanoma
- (2018) Chuan-Yuan Wei et al. ONCOGENE
- TRIM44 Is a Poor Prognostic Factor for Breast Cancer Patients as a Modulator of NF-κB Signaling
- (2017) Hidetaka Kawabata et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
- (2017) Rajesha Rupaimoole et al. NATURE REVIEWS DRUG DISCOVERY
- TRIM Family Proteins: Roles in Autophagy, Immunity, and Carcinogenesis
- (2017) Shigetsugu Hatakeyama TRENDS IN BIOCHEMICAL SCIENCES
- TRIM24 is an oncogenic transcriptional co-activator of STAT3 in glioblastoma
- (2017) Deguan Lv et al. Nature Communications
- Ubiquitin-specific protease 7 accelerates p14ARFdegradation by deubiquitinating thyroid hormone receptor-interacting protein 12 and promotes hepatocellular carcinoma progression
- (2015) Jia-Bin Cai et al. HEPATOLOGY
- A positive feedback between p53 and miR-34 miRNAs mediates tumor suppression
- (2014) N. Okada et al. GENES & DEVELOPMENT
- MicroRNAs in cancer: biomarkers, functions and therapy
- (2014) Josie Hayes et al. TRENDS IN MOLECULAR MEDICINE
- Novel Function of Trim44 Promotes an Antiviral Response by Stabilizing VISA
- (2013) B. Yang et al. JOURNAL OF IMMUNOLOGY
- In-Depth Characterization of microRNA Transcriptome in Melanoma
- (2013) James Kozubek et al. PLoS One
- The role of microRNAs in cancers of the upper gastrointestinal tract
- (2012) Shumei Song et al. Nature Reviews Gastroenterology & Hepatology
- CD151 Amplifies Signaling by Integrin α6β1 to PI3K and Induces the Epithelial–Mesenchymal Transition in HCC Cells
- (2011) Ai–Wu Ke et al. GASTROENTEROLOGY
- The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44
- (2011) Can Liu et al. NATURE MEDICINE
- The widespread regulation of microRNA biogenesis, function and decay
- (2010) Jacek Krol et al. NATURE REVIEWS GENETICS
- TRIM44 interacts with and stabilizes terf, a TRIM ubiquitin E3 ligase
- (2009) Tomohiko Urano et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started